Detalhe da pesquisa
1.
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Lancet Oncol
; 24(1): 64-76, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36528035
2.
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma.
Ann Hematol
; 100(2): 437-443, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33392702
3.
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.
Haematologica
; 105(4): 1074-1080, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31248973
4.
Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies.
Haematologica
; 99(10): 1611-7, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25015938
5.
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis.
J Cancer Res Clin Oncol
; 144(7): 1357-1366, 2018 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-29675792